(R)-DOTMA
(R)-DOTMA is a cationic lipid that can be used to construct lipid nanoparticles and lipoplexes. (R)-DOTMA binds nucleic acid molecules such as mRNA through electrostatic interactions, facilitating nucleic acid encapsulation and cellular delivery. (R)-DOTMA can form lipid systems with DOPE (HY-112005) or cholesterol (HY-N0322). (R)-DOTMA is applicable to mRNA delivery, vaccine development, cancer immunotherapy and gene editing research.
For research use only. We do not sell to patients.
- CAS No.: 2101981-60-4
- Formula: C42H84ClNO2
- Molecular Weight:670.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
(R)-DOTMA (2.75-4.32 mM; charge ratios 1.3:2.0, 4.0:1.0; 1 h, overnight) positively charged (4.0:1.0) (R)-DOTMA/DOPE and (R)-DOTMA/cholesterol lipoplexes have mean zeta potentials of +9.5 mV and mean particle sizes of 284 nm and 337 nm, respectively, while negatively charged (1.3:2.0) formulations have negative zeta potentials and smaller mean particle sizes of 212 nm ((R)-DOTMA/DOPE) and 235 nm ((R)-DOTMA/cholesterol)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
(R)-DOTMA (20 µg mRNA; retro-orbital injection; single dose) efficiently delivers Cre mRNA activity to all lung lobes (proximal and distal airways) via cationic DOTMA/cholesterol lipoplexes in ROSA26 lacZ Cre reporter mice, while cationic DOTMA/DOPE lipoplexes only target proximal lung areas and pulmonary vessel cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:White NMRI mice[1]
-
Dosage:20 µg mRNA (delivered in 200 µl isotonic lipoplex mixture); cationic DOTMA/DOPE (charge ratio 4.0:1.0); anionic DOTMA/DOPE (charge ratio 1.3:2.0); cationic DOTMA/cholesterol (charge ratio 4.0:1.0); anionic DOTMA/cholesterol (charge ratio 1.3:2.0)
-
Administration:retro-orbital injection; single dose
-
Result:Produced strong luciferase activity primarily in lungs with cationic formulations.
Produced strong luciferase activity primarily in spleen with anionic formulations.
Achieved highest luciferase expression in lungs with cationic DOTMA/cholesterol formulation.
Achieved highest luciferase expression in spleen with anionic DOTMA/DOPE formulation.
Showed no detectable luciferase activity in liver, except weak signal in heart with cationic DOTMA/cholesterol lipoplexes.
Accumulated predominantly in lungs, spleen, and liver, with no detectable levels in heart and kidneys via LC-MS analysis.
-
Animal Model:ROSA26 lacZ Cre reporter mice (FVB.129S4(B6)-Gt(ROSA)26Sortm1Sor/J)[1]
-
Dosage:20 µg mRNA (delivered in 200 µl isotonic lipoplex mixture); cationic DOTMA/DOPE (charge ratio 4.0:1.0); cationic DOTMA/cholesterol (charge ratio 4.0:1.0)
-
Administration:retro-orbital injection; single dose
-
Result:Targeted Cre mRNA activity to central areas of left, right cranial, middle, and caudal lung lobes, with no activity in right post caval lobe and no delivery to distal airways via cationic DOTMA/DOPE lipoplexes.
Delivered Cre mRNA activity only to proximal lung areas and pulmonary vessel cells via cationic DOTMA/DOPE lipoplexes.
Targeted all five lung lobes (both proximal and distal airways) with uniform staining of endothelial cells in small lung vessels via cationic DOTMA/cholesterol lipoplexes.
Showed no delivery of Cre mRNA activity to large airway cells with either formulation.
Showed no background X-Gal staining in control mice not injected with Cre mRNA.
Chemical Information
-
CAS No. 2101981-60-4
-
Molecular Weight 670.59
-
Formula C42H84ClNO2
-
SMILES
[C@@H](COCCCCCCCC/C=C\CCCCCCCC)(OCCCCCCCC/C=C\CCCCCCCC)C[N+](C)(C)C.[Cl-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Gene Editing
Gene editing modify specific sites within the genome through gene deletions, insertions or conversions to study functionally unknown genes or conduct gene therapy. It is also used to change the biological traits of organisms to establish new varieties. Gene editing techniques include zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas 9) (CRISPR/Cas9).
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
CRISPR-Cas9 editing of human pluripotent stem cells
CRISPR-Cas9 editing of human pluripotent stem cells uses a guide RNA to direct Cas9 to a genomic target, where Cas9 creates a double-strand break that is repaired mainly by non-homologous end joining for knockout mutations or by homology-directed repair when a donor template is supplied for precise knock-in or sequence correction. The readout is generated by genotyping edited bulk populations or single-cell-derived clones, using PCR, sequencing, restriction-based assays, reporter fluorescence, or allele-specific analysis to distinguish unedited alleles, indels, precise donor-mediated edits, biallelic deletions, and unwanted on-target lesions.
Purity & Documentation
References
[1]. Rosigkeit S, et al. Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice. Molecular pharmaceutics. 2018 Sep 04;15(9):3909-3919. [Content Brief]
[2]. Graewert MA, et al. Quantitative size-resolved characterization of mRNA nanoparticles by in-line coupling of asymmetrical-flow field-flow fractionation with small angle X-ray scattering. Scientific reports. 2023 Sep 22;13(1):15764. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)